Novo Nordisk’s Tresiba has been found to be efficient in treating diabetes compared to other basal insulins.
News
FDA grants Dupixent Priority Review for sinusitis
US regulators have accepted Sanofi’s Dupixent for Priority Review as a treatment for rhinosinusitis with nasal polyps.
NICE updates high blood pressure guidelines
NICE has published a draft updated guideline on the diagnosis and management of high blood pressure, with thousands more patients to qualify for treatment.
EMA validates Bavencio for review in advanced RCC
European regulators have validated Merck’s application Bavencio for review in kidney cancer.
32 cases of measles confirmed in Greater Manchester
Public health officials having confirmed a sharp rise of measles across Greater Manchester, leading to renewed calls for the public to ensure they are fully vaccinated against the disease.
Campaigners call for NHS access to Orkambi as MP inquiry gets underway
Patients and campaigners took to the streets in London yesterday demanding NHS access to Vertex’ cystic fibrosis drugs, following a public hearing on the situation ordered by MPs.
Allergan’s rapastinel fails to hit key targets in depression trials
Allergan’s rapastinel has failed to hit its primary endpoints in three late-stage studies assessing its potential as an adjunctive treatment for depression.
Vertex’ three-drug CF combo hits PhIII targets
Vertex’ three-drug cystic fibrosis regimen – combining the investigational next-generation corrector VX-445 with Kalydeco (ivacaftor) and tezacaftor – has achieved primary endpoints of two Phase III studies in patients the condition.
86% of Britain believe NHS faces a ‘major’ funding problem
Most people feel the NHS has a major funding problem, according to the 2018 British Social Attitudes (BSA) survey.
Researchers develop new prognostic test for colorectal cancer
High-risk stage two cancer patients could be identified more easily and accurately, due to a hopeful new prognostic method developed by researchers at the University of St Andrews.
FDA approves nasal spray for treatment-resistant depression
The FDA has approved Johnson & Johnson’s Spravato for treatment-resistant depression, offering patients the first new treatment option in several years.
NICE evidence request for Blincyto for acute lymphoblastic leukaemia
NICE has requested further evidence on Amgen’s Blincyto for the treatment of adults with acute lymphoblastic leukaemia.
Milestone reached as HIV remission achieved in second patient
A patient treated with a stem cell transplant has been in remission from HIV for 18 months and is no longer taking HIV drugs.
Delays to cancer testing and treatment ‘inevitable’ after Brexit
Delays to cancer testing and treatment will be “inevitable” as a result of a no-deal Brexit.
Scotland’s children at risk due to lack of doctors
Scotland’s lack of paediatric doctors is putting young people at risk, according to a new report by the Royal College of Paediatrics and Child Health (RCPCH).
